ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0054

TCR Immune Profiling of Patients with Psoriatic Disease

Ameth Garrido1, Rohan Machhar2, Omar Cruz Correa3, Sarah Crome4, Joan Wither3, Igor Jurisica5 and Dafna Gladman6, 1Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada, 2Krembil Research Institute, University Health Network, Toronto, ON, Canada, 3University Health Network, Toronto, ON, Canada, 4Ajmera Transplant Centre, Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, 5Schroeder Arthritis Institute, Krembil Research Institute, Toronto, ON, Canada, 6Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada

Meeting: ACR Convergence 2021

Keywords: Clonal Expansion, psoriasis, Psoriatic arthritis, single cell RNA sequencing, TCR sequencing

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: CD8+ and CD4+ T cell subsets have been implicated in the pathogenesis of psoriatic disease. Here, we explore the T-cell repertoire in psoriatic disease using single-cell RNA sequencing to identify novel susceptibility markers of disease by focusing on T cells with clonal expansion.

Methods: We profiled frozen peripheral blood mononuclear cells derived from 3 psoriasis, 3 psoriatic arthritis (biologic naïve, matched for age, gender and disease duration) and 2 healthy control samples using 10X genomics 5’ single cell gene expression technology. TCR immune cell profiling was employed, and sequencing data was processed using the CELLRANGER pipeline. We identified 4579 TCRs in psoriasis, 3323 in psoriatic arthritis, and 1843 in healthy control samples. Secondary analysis of TCR beta and alpha chains was conducted in R version 4.0.1 using scran, scater, SingleCellExperiment, Seurat, scREPERTOIRE and Immunarch. The online tool GLIPH2.0 was used to cluster the TCR beta CDR3 amino acid sequences based on motif similarity and VDJdb was used to predict antigen specificity. VDJ gene differential expression analysis was conducted across multiple groups using the Dunn.test function in R.

Results: The shared motifs from the clustering results from GLIPH2.0 comprising only psoriatic arthritis and/or psoriasis patients had a predicted antigen specificity for Cytomegalovirus (CMV) proteins Immediate-Early1 (IE1) or pp65. The variable beta chain genes TRBV2 (FC= 0.14, p-value= 0.033), TRBV7-2(FC=1.49, p-value= 0.0098), TRBV7-7(FC=1.00, p-value= 0.018) and TRBV6-3 (FC= 1.17, p-value=0.033) were elevated and significantly differentially expressed in psoriatic arthritis patients when compared to psoriasis patients. A clonal expansion of CD8+ cytotoxic T-cells was observed in a psoriatic arthritis patient. It accounted for approximately 7% of all clonotypes for that individual. The predicted antigen was IE1 from CMV.

Conclusion: Antigen selection may be occurring in psoriatic arthritis patients. Further investigation is required to determine if the predicted antigens pp65 and IE1 are relevant in the pathogenesis of psoriatic arthritis.


Disclosures: A. Garrido, None; R. Machhar, None; O. Cruz Correa, None; S. Crome, None; J. Wither, None; I. Jurisica, None; D. Gladman, AbbVie, 2, 5, Amgen, 2, 5, Eli Lilly, 2, 5, Galapagos, 2, 5, Gilead, 2, 5, Janssen, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, UCB, 2, 5, Celgene, 2, 5, Bristol Myers Squibb, 2, 5.

To cite this abstract in AMA style:

Garrido A, Machhar R, Cruz Correa O, Crome S, Wither J, Jurisica I, Gladman D. TCR Immune Profiling of Patients with Psoriatic Disease [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/tcr-immune-profiling-of-patients-with-psoriatic-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tcr-immune-profiling-of-patients-with-psoriatic-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology